Table 4.

Carotid CMR total wall volume changes in the ITT population

	Treatment Group
Week 52	Rosiglitazone	Placebo
(mm3)	(N = 25)	(N = 29)
Number with baseline and week 52 CMR scans	21	26
Baseline (mean ± SD)	1354 ± 532	1146 ± 550
End of treatment (mean ± SD)	1348 ± 531	1134 ± 523
Change from baseline
mean ± SD	-5.7 ± 79.4	-12.1 ± 104.6
Model adjusted change from baseline1
mean ± SE	12.7 ± 22.8	-2.9 ± 20.9
Difference from placebo1
mean	15.7	-
95% CI	-39.5, 70.9	-
P-value	0.57	-

1. Adjusted for stratum + baseline value + treatment.